{"pmid":32368755,"pmcid":"PMC7196388","title":"A Recovered Case of COVID-19 Myocarditis and ARDS Treated with Corticosteroids, Tocilizumab, and Experimental AT-001.","text":["A Recovered Case of COVID-19 Myocarditis and ARDS Treated with Corticosteroids, Tocilizumab, and Experimental AT-001.","We describe the case of a critically-ill patient with myocarditis and severe ARDS related to COVID-19 infection. This case highlights management strategies including the use of corticosteroids, an IL-6 inhibitor, and an aldose reductase inhibitor resulting in complete clinical recovery.","JACC Case Rep","Coyle, Justin","Igbinomwanhia, Efehi","Sanchez-Nadales, Alejandro","Danciu, Sorin","Chu, Chae","Shah, Nishit","32368755"],"abstract":["We describe the case of a critically-ill patient with myocarditis and severe ARDS related to COVID-19 infection. This case highlights management strategies including the use of corticosteroids, an IL-6 inhibitor, and an aldose reductase inhibitor resulting in complete clinical recovery."],"journal":"JACC Case Rep","authors":["Coyle, Justin","Igbinomwanhia, Efehi","Sanchez-Nadales, Alejandro","Danciu, Sorin","Chu, Chae","Shah, Nishit"],"date":"2020-05-06T11:00:00Z","year":2020,"_id":"32368755","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/j.jaccas.2020.04.025","keywords":["2019-ncov","ards","covid-19","sars-cov-2","aldose reductase inhibitor","cardiac mri","cardiogenic shock","corticosteroids","myocarditis","tocilizumab"],"e_drugs":["tocilizumab"],"topics":["Case Report"],"weight":1,"_version_":1666138496253820928,"score":9.490897,"similar":[{"pmid":32367812,"title":"[First case of COVID-19 treated with tocilizumab in Iceland].","text":["[First case of COVID-19 treated with tocilizumab in Iceland].","A gentleman in his early fifties became ill with flu-like symptoms after vacationing abroad and was diagnosed with COVID-19 after returning to Iceland. A few days later he was admitted to the University Hospital, Landspitali, due to worsening respiratory symptoms and severe fatigue. A computed tomography scan of lthe lungs showed diffuse bilateral consolidations and ground glass changes. He developed respiratory failure and was transferred to the intensive care unit where he received further treatment, including tocilizumab (IL-6 receptor inhibitor). He subsequently showed clinical improvement and did not require endotracheal intubation.","Laeknabladid","Bjornsson, Aron Hjalti","Olafsdottir, Thorbjorg","Thormar, Katrin Maria","Kristjansson, Mar","Thorisdottir, Anna Sesselja","Ludviksson, Bjorn Runar","Guethmundsson, Sigurdur","Gottfredsson, Magnus","32367812"],"abstract":["A gentleman in his early fifties became ill with flu-like symptoms after vacationing abroad and was diagnosed with COVID-19 after returning to Iceland. A few days later he was admitted to the University Hospital, Landspitali, due to worsening respiratory symptoms and severe fatigue. A computed tomography scan of lthe lungs showed diffuse bilateral consolidations and ground glass changes. He developed respiratory failure and was transferred to the intensive care unit where he received further treatment, including tocilizumab (IL-6 receptor inhibitor). He subsequently showed clinical improvement and did not require endotracheal intubation."],"journal":"Laeknabladid","authors":["Bjornsson, Aron Hjalti","Olafsdottir, Thorbjorg","Thormar, Katrin Maria","Kristjansson, Mar","Thorisdottir, Anna Sesselja","Ludviksson, Bjorn Runar","Guethmundsson, Sigurdur","Gottfredsson, Magnus"],"date":"2020-05-06T11:00:00Z","year":2020,"_id":"32367812","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.17992/lbl.2020.05.581","keywords":["covid-19","coronavirus","cytokine storm","sars-cov-2","tocilizumab"],"locations":["Iceland","Landspitali","Iceland"],"countries":["Iceland"],"countries_codes":["ISL|Iceland"],"e_drugs":["tocilizumab"],"topics":["Case Report"],"weight":1,"_version_":1666138496239140864,"score":155.25977},{"pmid":32391369,"pmcid":"PMC7193030","title":"Use of Corticosteroids in Coronavirus Disease 2019 Pneumonia: A Systematic Review of the Literature.","text":["Use of Corticosteroids in Coronavirus Disease 2019 Pneumonia: A Systematic Review of the Literature.","The aim was to investigate the effectiveness of glucocorticoid therapy in patients with COVID-19. A systematic search of the literature across nine databases was conducted from inception until 15th March 2020, following the PRISMA guidelines. Patients with a validated diagnosis of COVID-19 and using corticosteroids were included, considering all health outcomes. Four studies with 542 Chinese participants were included. Two studies reported negative findings regarding the use of corticosteroids in patients with COVID-19, i.e., corticosteroids had a detrimental impact on clinical outcomes. One study reported no significant association between the use of corticosteroids and clinical outcomes. However, one study, on 201 participants with different stages of pneumonia due to COVID-19, found that in more severe forms, the administration of methylprednisolone significantly reduced the risk of death by 62%. The literature to date does not fully support the routine use of corticosteroids in COVID-19, but some findings suggest that methylprednisolone could lower mortality rate in more severe forms of the condition.","Front Med (Lausanne)","Veronese, Nicola","Demurtas, Jacopo","Yang, Lin","Tonelli, Roberto","Barbagallo, Mario","Lopalco, Pierluigi","Lagolio, Erik","Celotto, Stefano","Pizzol, Damiano","Zou, Liye","Tully, Mark A","Ilie, Petre Cristian","Trott, Mike","Lopez-Sanchez, Guillermo F","Smith, Lee","32391369"],"abstract":["The aim was to investigate the effectiveness of glucocorticoid therapy in patients with COVID-19. A systematic search of the literature across nine databases was conducted from inception until 15th March 2020, following the PRISMA guidelines. Patients with a validated diagnosis of COVID-19 and using corticosteroids were included, considering all health outcomes. Four studies with 542 Chinese participants were included. Two studies reported negative findings regarding the use of corticosteroids in patients with COVID-19, i.e., corticosteroids had a detrimental impact on clinical outcomes. One study reported no significant association between the use of corticosteroids and clinical outcomes. However, one study, on 201 participants with different stages of pneumonia due to COVID-19, found that in more severe forms, the administration of methylprednisolone significantly reduced the risk of death by 62%. The literature to date does not fully support the routine use of corticosteroids in COVID-19, but some findings suggest that methylprednisolone could lower mortality rate in more severe forms of the condition."],"journal":"Front Med (Lausanne)","authors":["Veronese, Nicola","Demurtas, Jacopo","Yang, Lin","Tonelli, Roberto","Barbagallo, Mario","Lopalco, Pierluigi","Lagolio, Erik","Celotto, Stefano","Pizzol, Damiano","Zou, Liye","Tully, Mark A","Ilie, Petre Cristian","Trott, Mike","Lopez-Sanchez, Guillermo F","Smith, Lee"],"date":"2020-05-12T11:00:00Z","year":2020,"_id":"32391369","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.3389/fmed.2020.00170","keywords":["ards","covid-19","sars-cov-2","coronavirus","corticosteroids","methylprednisolone","pneumonia"],"locations":["Chinese"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["Methylprednisolone"],"topics":["Treatment"],"weight":1,"_version_":1666528580116414464,"score":141.72736},{"pmid":32421092,"pmcid":"PMC7224649","title":"SARS-CoV-2 and COVID-19: is interleukin-6 (IL-6) the 'culprit lesion' of ARDS onset? What is there besides Tocilizumab? SGP130Fc.","text":["SARS-CoV-2 and COVID-19: is interleukin-6 (IL-6) the 'culprit lesion' of ARDS onset? What is there besides Tocilizumab? SGP130Fc.","Since the outbreak of COVID-19 many studies have been published showing possible therapies, here the author discusses the end of stage disease related drugs, like Tocilizumab which is currently being used in ARDS patients. In some patients, disease progression leads to an enormous secretion of cytokines, known as cytokine storm, among those cytokines IL-6 plays an important role. Here the author shows how IL-6 has both pro and anti-inflammatory properties, depending on the pathway of transduction: soluble (trans-signaling) or membrane-related (classic signaling), and suggests how targeting only the pro-inflammatory pathway, with SGP130Fc, could be a better option then targeting them both. Other possible IL-6 pathway inhibitors such as Ruxolitinib and Baricinitib are then analyzed, underlying how they lack the benefit of targeting only the pro-inflammatory pathway.","Cytokine X","Magro, Giuseppe","32421092"],"abstract":["Since the outbreak of COVID-19 many studies have been published showing possible therapies, here the author discusses the end of stage disease related drugs, like Tocilizumab which is currently being used in ARDS patients. In some patients, disease progression leads to an enormous secretion of cytokines, known as cytokine storm, among those cytokines IL-6 plays an important role. Here the author shows how IL-6 has both pro and anti-inflammatory properties, depending on the pathway of transduction: soluble (trans-signaling) or membrane-related (classic signaling), and suggests how targeting only the pro-inflammatory pathway, with SGP130Fc, could be a better option then targeting them both. Other possible IL-6 pathway inhibitors such as Ruxolitinib and Baricinitib are then analyzed, underlying how they lack the benefit of targeting only the pro-inflammatory pathway."],"journal":"Cytokine X","authors":["Magro, Giuseppe"],"date":"2020-05-19T11:00:00Z","year":2020,"_id":"32421092","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.cytox.2020.100029","keywords":["baricitinib","covid-19","il-6","il-6 trans-signaling","interleukin-6","ruxolitinib","sars-cov-1","sars-cov-2","sgp130fc","tocilizumab","coronavirus","coronaviruses","drugs","strategies","targets","therapies"],"e_drugs":["INCB018424","tocilizumab"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667159284554661888,"score":138.56027},{"pmid":32413736,"pmcid":"PMC7205724","title":"Towards treatment planning of COVID-19: Rationale and hypothesis for the use of multiple immunosuppressive agents: Anti-antibodies, immunoglobulins, and corticosteroids.","text":["Towards treatment planning of COVID-19: Rationale and hypothesis for the use of multiple immunosuppressive agents: Anti-antibodies, immunoglobulins, and corticosteroids.","The novel coronavirus, SARS-CoV2, can cause a potentially fatal disease, COVID-19, in humans. Here, we will provide an overview of therapeutic options for COVID-19. Plasma from patients recovered from COVID-19 that contains antibodies against SARS-CoV2 has shown promising results in patients with severe COVID-19. Also, IVIG, combined with moderate-dose of corticosteroids, might improve patient outcomes. Evidence links COVID-19 to variable degrees of inflammation. Studies show that the use of corticosteroids might accelerate recovery from COVID-19. There are, however, no controlled clinical trials that show whether the use of corticosteroids can reduce COVID-19-related death. Also, the pro-inflammatory cytokine IL6 is the best-documented cytokine in COVID-19 correlated with severity, criticality, viral load, and prognosis of patients with COVID-19. Tocilizumab, a monoclonal antibody against IL6, could confer clinical benefit in patients with high IL6 levels. Essential elements that process SARS-CoV2 cell entry and specific characteristics that allow SARS-CoV2 to escape the immune system have the potential as targets for COVID-19 therapy.","Int Immunopharmacol","Saghazadeh, Amene","Rezaei, Nima","32413736"],"abstract":["The novel coronavirus, SARS-CoV2, can cause a potentially fatal disease, COVID-19, in humans. Here, we will provide an overview of therapeutic options for COVID-19. Plasma from patients recovered from COVID-19 that contains antibodies against SARS-CoV2 has shown promising results in patients with severe COVID-19. Also, IVIG, combined with moderate-dose of corticosteroids, might improve patient outcomes. Evidence links COVID-19 to variable degrees of inflammation. Studies show that the use of corticosteroids might accelerate recovery from COVID-19. There are, however, no controlled clinical trials that show whether the use of corticosteroids can reduce COVID-19-related death. Also, the pro-inflammatory cytokine IL6 is the best-documented cytokine in COVID-19 correlated with severity, criticality, viral load, and prognosis of patients with COVID-19. Tocilizumab, a monoclonal antibody against IL6, could confer clinical benefit in patients with high IL6 levels. Essential elements that process SARS-CoV2 cell entry and specific characteristics that allow SARS-CoV2 to escape the immune system have the potential as targets for COVID-19 therapy."],"journal":"Int Immunopharmacol","authors":["Saghazadeh, Amene","Rezaei, Nima"],"date":"2020-05-16T11:00:00Z","year":2020,"_id":"32413736","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.intimp.2020.106560","keywords":["covid-19","corticosteroids","immunoglobulin","interleukin 6","targeted therapy","treatment"],"e_drugs":["tocilizumab"],"topics":["Treatment"],"weight":1,"_version_":1666989866115661824,"score":136.9554},{"pmid":32363334,"pmcid":"PMC7194983","title":"Cardiovascular Collapse in COVID-19 Infection: The Role of Veno-Arterial Extracorporeal Membrane Oxygenation (VA-ECMO).","text":["Cardiovascular Collapse in COVID-19 Infection: The Role of Veno-Arterial Extracorporeal Membrane Oxygenation (VA-ECMO).","COVID-19 has been associated with cardiovascular complications including acute cardiac injury, heart failure and cardiogenic shock. The role of veno-arterial extracorporeal membrane oxygenation (VA-ECMO) in the event of COVID-19-associated cardiovascular collapse has not yet been established. We reviewed existing literature surrounding the role of VA-ECMO in the treatment of coronavirus-related cardiovascular collapse. COVID-19 is associated with higher incidence of cardiovascular complications compared to previous coronavirus outbreaks (SARS-CoV, MERS-CoV). We found only one case report from China where COVID-19-associated fulminant myocarditis and cardiogenic shock (CS) was successfully rescued using VA-ECMO as a bridge to recovery (BTR). We identified potential clinical scenarios (cardiac injury, myocardial infarction with and without obstructive coronary artery disease, viral myocarditis, and decompensated heart failure) leading to CS and risk factors for poor/uncertain benefit (age, sepsis, mixed/predominantly vasodilatory shock, prothrombotic state and/or coagulopathy, severe acute respiratory distress syndrome, multi-organ failure or high-risk prognostic scores) specific to using VA-ECMO as BTR in COVID-19 infection. Additional considerations and proposed recommendations specific to the COVID-19 pandemic were formulated with guidance from published data and expert consensus. A small subset of patients with cardiovascular complications from COVID-19 infection may progress to refractory CS. Accepting that resource scarcity may be the overwhelming concern for healthcare systems during this pandemic, VA-ECMO can be considered in highly selected cases of refractory CS and echocardiographic evidence of biventricular failure. The decision to initiate this therapy should take into consideration availability of resources, perceived benefit as well as risks of transmitting disease.","CJC Open","Chow, Justin","Alhussaini, Anhar","Calvillo-Arguelles, Oscar","Billia, Filio","Luk, Adriana","32363334"],"abstract":["COVID-19 has been associated with cardiovascular complications including acute cardiac injury, heart failure and cardiogenic shock. The role of veno-arterial extracorporeal membrane oxygenation (VA-ECMO) in the event of COVID-19-associated cardiovascular collapse has not yet been established. We reviewed existing literature surrounding the role of VA-ECMO in the treatment of coronavirus-related cardiovascular collapse. COVID-19 is associated with higher incidence of cardiovascular complications compared to previous coronavirus outbreaks (SARS-CoV, MERS-CoV). We found only one case report from China where COVID-19-associated fulminant myocarditis and cardiogenic shock (CS) was successfully rescued using VA-ECMO as a bridge to recovery (BTR). We identified potential clinical scenarios (cardiac injury, myocardial infarction with and without obstructive coronary artery disease, viral myocarditis, and decompensated heart failure) leading to CS and risk factors for poor/uncertain benefit (age, sepsis, mixed/predominantly vasodilatory shock, prothrombotic state and/or coagulopathy, severe acute respiratory distress syndrome, multi-organ failure or high-risk prognostic scores) specific to using VA-ECMO as BTR in COVID-19 infection. Additional considerations and proposed recommendations specific to the COVID-19 pandemic were formulated with guidance from published data and expert consensus. A small subset of patients with cardiovascular complications from COVID-19 infection may progress to refractory CS. Accepting that resource scarcity may be the overwhelming concern for healthcare systems during this pandemic, VA-ECMO can be considered in highly selected cases of refractory CS and echocardiographic evidence of biventricular failure. The decision to initiate this therapy should take into consideration availability of resources, perceived benefit as well as risks of transmitting disease."],"journal":"CJC Open","authors":["Chow, Justin","Alhussaini, Anhar","Calvillo-Arguelles, Oscar","Billia, Filio","Luk, Adriana"],"date":"2020-05-05T11:00:00Z","year":2020,"_id":"32363334","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/j.cjco.2020.04.003","keywords":["extracorporeal membrane oxygenation","cardiogenic shock","coronavirus","mechanical circulatory support","myocarditis"],"locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1666138496055640065,"score":132.16089}]}